Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aptose Biosciences, Inc.

< Previous 1 2 Next >
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTOF TSX:APS
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTOF TSX:APS
Aptose Reports First Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTOF TSX:APS
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Auditor Not Standing for Re-Appointment
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Year End 2024 Results and Corporate Highlights
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Reverse Share Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Positive Decision by Nasdaq Hearings Panel
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Third Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Results from Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Adjournment of its Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Second Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Receipt of Deficiency Notice from Nasdaq
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.